Table 3.
Reversal of chemoresistance
| Target | Inhibitors | Cancers | Resistant drugs or sensitized drugs | References |
|---|---|---|---|---|
| BRD4 | JQ1 | Ovarian cancer | Cisplatin | [45, 119] |
| NSCLC | TRAIL, cisplatin | [142] | ||
| Breast cancer | Salinomycin | [121] | ||
| Breast cancer | AKTi | [170] | ||
| Melanoma | Vemurafenib | [171] | ||
| PDAC | 5-FU | [176] | ||
| I-BET151 | MCL | Ibrutinib, lenalidomide | [140] | |
| TNBC | Trametinib | [194] | ||
| I-BET762 | NSCLC | TRAIL, cisplatin | [142] | |
| OTX-015 | NSCLC | TRAIL, cisplatin | [142] | |
| SR2211 | Pancreatic adenocarcinoma | Gemcitabine | [117] | |
| ARV-771 | MCL | Ibrutinib, venetoclax, palbociclib | [177] | |
| MS417 | Breast cancer | AKTi | [170] | |
| H3K27ac | TSA | Glioblastoma | Temozolomide | [183] |
| CDK7 | THZ1 | B cell lymphoma | ABT-199 | [191] |
| CDK12 | THZ531 | Anaplastic thyroid carcinoma | Doxorubicin | [192] |
NSCLC non-small cell lung cancer, PDAC pancreatic ductal adenocarcinoma, MCL mantle cell lymphoma, TNBC triple-negative breast cancer, AKTi AKT inhibitor, TRAIL tumor necrosis factor-related apoptosis-inducing ligand